Blog
RSS FeedPosted by Michael Wonder on 12 Oct 2020
SMC accepts Bavencio (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
12 October 2020 - Merck and Pfizer announced today that the Scottish Medicines Consortium has accepted the immunotherapy Bavencio (avelumab) for ...
Posted by Michael Wonder on 12 Oct 2020
SMC - October 2020 decisions
12 October 2020 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 09 Sep 2020
Alimera Sciences obtains reimbursement approval for Iluvien use in non-infectious posterior uveitis in Scotland
8 September 2020 - Alimera Sciences announces that the Scottish Medicines Consortium, after completing its assessment and review, has accepted (per ...
Posted by Michael Wonder on 07 Sep 2020
SMC recommends Merck's Keytruda for another two indications
7 September 2020 - Pembrolizumab (Keytruda) has been accepted for the treatment of patients with head and neck squamous cell carcinoma ...
Posted by Michael Wonder on 07 Sep 2020
SMC accepts Spravato (esketamine) nasal spray for use in adults with treatment-resistant major depressive disorder in Scotland
7 September 2020 - SMC acceptance comes less than a week after second rejection by NICE. ...
Posted by Michael Wonder on 07 Sep 2020
SMC - September 2020 decisions
7 September 2020 - The SMC has today published advice accepting fourteen new medicines. ...
Posted by Michael Wonder on 10 Aug 2020
SMC - August 2020 decisions
10 August 2020 - The Scottish Medicines Consortium has today published advice accepting neratinib (Nerlynx) for the treatment of breast ...
Posted by Michael Wonder on 14 Apr 2020
SMC - April 2020 decisions
13 April 2020 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today published ...
Posted by Michael Wonder on 09 Mar 2020
SMC - March 2020 decisions
9 March 2020 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 11 Feb 2020
SMC approves first two ‘ultra-orphan’ pathway meds
11 February 2020 - The Scottish Medicines Consortium has released its February guidance, advising six new medicines to NHS Scotland. ...
Posted by Michael Wonder on 11 Feb 2020
SMC - February 2020 decisions
10 February 2020 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 13 Jan 2020
SMC - January 2020 decisions
13 January 2020 - Medicines which can be used to treat prostate cancer, primary progressive multiple sclerosis, a rare form ...
Posted by Michael Wonder on 12 Dec 2019
NICE and the SMC have published recommendations on Shionogi’s Mulpleo (lusutrombopag), approving its use for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
12 December 2019 - Mulpleo (lusutrombopag) is the first licensed treatment to be made available through the National Health Service ...
Posted by Michael Wonder on 10 Dec 2019
Ovarian cancer drug olaparib approved in Scotland as new treatment
9 December 2019 - A maintenance treatment for patients with advanced ovarian cancer has been approved for use in Scotland. ...
Posted by Michael Wonder on 09 Dec 2019
SMC - December 2019 decisions
9 December 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...